Exclusion criteria: Group 1 (sepsis patients): neuromuscular diseases, alcohol abuse, steroid therapy for asthma, COPD and patients likely to die within less than 24 hours, patients after tonsillectomy<br>Group 2 and 3 (chronic tonsillitis and tonsil hyperplasia): sepsis, immunodeficiency, severe chronic diseases in the medical history
Exclusion criteria: Patients younger than 18 years or with contraindication to a contrast-enhanced CT scan.
Exclusion criteria: <18 years; operational coronary heart disease; acute myocardial infarction; TIA, PRIND, Apoplex in the last 6 months, no patient consent
Exclusion criteria: pregnancy, acute myocardial infarction or stroke within 14 days before the examination
Exclusion criteria: is not able to give consent ot take part in that study, is not able to understand and/or fill in the questionaire SF-36 and other forms
Exclusion criteria: - lack of consentability <br>- lack of consent for participation <br>- incomplete or nonevaluable data<br>- preoperative spontaneous resorption of the calcification<br>- relevant additional intraoperative pathologies <br>- reoperation
Exclusion criteria: 1. Mucosal or ocular melanoma melanoma<br>2. Intransitmetastasen<br>3. Other adjuvant therapy (systemic therapy with an immunomodulator of a previous operation is allowed, provided that the last dose at least 30 days earlier; prior radiotherapy before lymphadenectomy is allowed)<br>4. Autoimmune disorders (vitiligo außgenommen)<br>5. Immunodeficiency<br>6. Other malignancies (excluding carcinoma in situ of the cervix or remission over 5 years)<br>7. Uncontrolled bleeding
Exclusion criteria: Patients who<br>have a known allergy to constituents of the materials used, are addicted to medication, alcohol and/ or drugs, are suffering from infectious diseases (hepatitis, HIV, tuberculosis), are suffering from malignant tumors, are undergoing or have undergone radiotherapy, are pregnant or breast feeding, are not giving informed consent, are applying for renewal of a telescopic denture, that is already present
Exclusion criteria: Exclusion criteria were contraindications to the use of electrical stimulation such as the presence of cardiac pacemakers or other implanted electronic devices, severe<br>cardiac arrhythmia, osteosyntheses, malignant tumors, neurological diseases, peripheral vascular diseases, pregnancy, breastfeeding women, haemophilia, skin or soft tissue disease or chronic pain syndromes such as migraine or back pain. Previous experience with electrical stimulation methods was also an exclusion criteria inorder to avoid an expectation bia
Exclusion criteria: presence of multiple defects which cannot adequately covered by implantation of one device, current participation in another ongoing clinical device or drug trial, recent myocardial infarction, unstable angina and decompensated congestive heart failure (CHF), active bacterial and/or viral infection, evidence of intra-cardiac thrombi on echocardiography, any existent disorder that, in opinion of the investigator, might interfere with the conduct of the trial
Exclusion criteria: No documented triple-class resistance, medical illness that does not allow safe blood draw, age under 18 years, cognitive impairment leading to inability to fill out the questionnaires and/or to give informed assent or consent.
Exclusion criteria: Students who did not pass one of those courses in the first attempt and therefore repeat it.
Exclusion criteria: Age under 18; no intervention or no surgery during hospitalisation
Exclusion criteria: Hospitals without intensive care units
Exclusion criteria: The investigator is clinically not convinced about vitrectomy being indicated or the possible side effects outweigh the possible positive effects of vitrectomy<br>- - - Diabetes mellitus type 1<br>- - - Visual acuity of the study eye (decimal) > 0,3 (LogMar   1,3)<br>- - - Central retinal thickness stated by SD-OCT   10 % or if it can be expected that the patient’s diabetes cannot be controlled adequately during the trial <br>- - - Uncontrolled arterial Hypertension defined as a systolic value of > 180 mmHg and/or a diastolic value of > 110 mmHg<br>- - - Systemic therapy with steroids or anticoagulative therapy with coumarin derivatives or heparin (Aspirin or Clopidogrel is allowed)<br>- - - History of allergy to fluorescein or ranibizumab<br>- - - Women who are pregnant or planning a pregnancy<br>- - - Women who are breast feeding<br>- - - Inability to comply with study or follow-up procedures
Exclusion criteria: oncological patients who are hospitalized with suspected ADR/ME and who have been hospitalized in the previous 4 weeks for oncological<br>treatment
Exclusion criteria: • Patients under 18 years<br>• Polytoxicomania<br>• Allergies to the various herbal ingredients of EUSANO formulation (food intolerance)<br>• Pregnancy
Exclusion criteria: no ability of giving consent;<br>aphasia, dementia, confusion of the patient;<br><br>for incidence study only: place of residences out of Essen and surrounding area
Exclusion criteria: lack of consent<br>preexisting severe lung disease (COPD, asthma)<br>gravidity
Exclusion criteria: hormone replacement therapy; history of breast cancer; serious health problems related to nutrient absorption, digestion, metabolism or excretion; women taking nutritional supplements or on medication during the past 3 months, which may interact with study parameters; participants who are supposed to be not complient;
Exclusion criteria: Knee arthrosis Grade 2 (Kellgren and Lawrence system)<br>Chronic drug abuse<br>Patients carrying, artifical heart waves, heart pacemaker, other ferromagnetic implants
Exclusion criteria: not German-speaking, not member of the rehabilitation team, age <18 years
Exclusion criteria: revocation of consent and underage patients
Exclusion criteria: - Body weight above 120kg <br>- Orthopedic problems and spasticity which make it impossible to walk with EB   <br>- cardio-pulmonary not tenable<br>- patients with aphasia, who don’t understand instructions<br>- patients with neglect
Exclusion criteria: Pregnancy, breast feeding, skin diseases, diseases of the peripheral nervous system, intake of antihistamines, NSAIDs, local anesthetics or mast cell stabilizers within 5 days prior to testing, intake of antideppressants within 14 days prior to testing, intake of steroids (topical or systemic) within 7 days prior to testing.
Exclusion criteria: Unrealistic expectations <br>• limitations that are inherent in clinical study<br>• Unwillingness or inability of / the candidate concerning the experimental requirements<br>• Additional disadvantages which would limit the participation in the audiological tests
Exclusion criteria: known cardiocirculatory diseases, known lung diseases, pregnancy, active implants
Exclusion criteria: Patients with evidence for a gemistocytic histology.
Exclusion criteria: CDR memory value = 2 or MMSE = 9; severe Alzheimer's disease, frontotemporal dementia, levy body dementia, dementia in Parkinson's disease, other rare forms of dementia (corticobasal degeneration, Korsakoff's disease, Creutzfeldt-Jakob disease, PCA), severe psychiatric illness or previous illness (drug or alcohol abuse / - looking for the last 5 years, acute suicidality), brain tumor, cerebral hemorrhage, stroke, traumatic brain injury, acute inflammatory diseases of the CNS, hydrocephalus
Exclusion criteria: Persons aged under 18, Wound infection before surgery, missing informed consent
Exclusion criteria: other illness of lower extremity; other neurological or psychiatric desease; no independent walking or sit to stand before; cardiorespiratory instability at T0; need for vasopressive support, severe illness of lumbar, thoracic or cervical spine, severe open wounds (abdomial, legs, pelvis), PAD >2, amputations upper limb, transfer to an other rehabilitation or intensiv care unit in the first 3 Weeks after adission; palliative care; dialyses more than 3 times/week, BMI: >35kg/m2
Exclusion criteria: (1) cognitive impairment indicating a possible dementia, (2) the presence of uncontrolled cardiac illness, (3) functional relevant disease (e.g. neurological and/or orthopedic), which significantly influences walking performance or leg extension, and (4) terminal illness
Exclusion criteria: Psychotic Disorder (acute or lifetime); Self-endangerment; current substance disorder; current personality disorder except avoidant, compulsive or dependent personality disorder; organically caused mental disorder; serious physical illness; current psychotherapeutic or psychopharmacological treatment
Exclusion criteria: Individuals for whom adequate CRC related screening measures already exist are excluded from the study. In particular, patients with an increased risk of CRC due to a known disease (family history of adenomatous polyposis, chronic inflammatory bowel diseases (ulcerative colitis, Chron's disease)) or with a  previous diagnosis of CRC will be excluded, as well as patients over 50 years of age for whom CRC screening already exists.
Exclusion criteria: Exclusion Criteria: - Participants who have previously demonstrated nonresponse of depressive symptoms to esketamine or ketamine in the current major depressive episode, to all 4 of the oral antidepressant treatment options available for the double-blind induction phase (ie, duloxetine, escitalopram, sertraline, and venlafaxine extended release [XR]) in the current major depressive episode (based on MGH-ATRQ), or an adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral ECT – Participant currently has an implant for vagal nerve stimulation (VNS) or has received deep brain stimulation (DBS) in the current episode of depression - Participant has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with psychosis, bipolar or related disorders (confirmed by the MINI), comorbid obsessive compulsive disorder, intellectual disability (only DSM-5 diagnostic code 319), borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder - Participant has homicidal ideation/intent, per the investigator’s clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening/prospective observational phase, per the investigator’s clinical judgment or based on the Columbia Suicide Severity Rating Scale (CSSRS) - Participants with history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria
Exclusion criteria: 1. Any contraindications for chemotherapy according to the Folfiri regimen<br>2. Non-curatively treated malignancy within the last 5 years<br>3. Uncontrolled or insulin-depending diabetes mellitus<br>4. Evidence of central nervous system (CNS) metastases<br>5. Uncontrolled infection<br>6. Significant cardiac disease (unstable angina pectoris or cardia symptoms according to New York Heart Association [NYHA] classification III or IV)<br>7. Active serious illness which renders the patient unsuitable for study entrance or multiple blood sampling<br>8. Pregnancy and lactation<br>9. History of hypersensitivity to cetuximab or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product<br>10. Participation in other clinical trials or observation period of competing trials, respectively <br>11. No patient will be allowed to enrol in this trial more than once
Exclusion criteria: <br>- Pre- treatment with ASS or other anticoagulant medication within the last 6 weeks <br>- Pre-treatment with lipid-lowering agents within the last 6 weeks <br>- Thrombolysis in acute stroke <br>- Previous stroke<br>- Malignant systemic disease<br>- Dementia<br>- Bathel-Index > 1<br>- Known liver damage or persistent ellevation of liver enzymes<br>- Known or current abuse of drugs, medications or alcohol<br>- Subjects unlikely to comply with the requirements of the protocol<br>- Pregnancy or lactation<br>- Women with child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they meet the following definition of post-menopausal: 12 month of natural (spontaneous) amenorrhea or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using a highly effective method of birth control (defined as those which result in a low failure rate, i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner<br>- Participation in another clinical trial within the last 4 weeks<br>
Exclusion criteria: <br>                1. Patients with metastatic disease<br>                2. Prior irradiation at the same site<br>                3. Planned use of protons<br>                4. Breast patients receiving concomitant chemo-radiation<br>                5. Male breast cancer patients<br>                6. Mastectomy patients<br>                7. Bilateral breast cancer<br>                8. Small cell lung cancer<br>                9. Mental disability or patient otherwise unable to give informed consent and/or complete patient questionnaires<br>                10. Limited life expectancy due to co-morbidity<br>                11. Pregnant patients<br>                12. Partial breast irradiation<br>                13. Patients with breast implants if not removed during surgery<br>                14. Patients with known HIV infection/infectious hepatitis<br>
Exclusion criteria: 1. Born <37 weeks gestational age<br>2. Known chromosomal and/or structural anomaly<br>3. Multiple gestation<br>4. Mothers with cardiac heart disease<br>5. Mothers’ severe systemic disease<br>6. Antihypertensive medication<br>7. Antenatal intra-uterine infection<br>
Exclusion criteria: 1. Patients with alcohol or drug addiction<br>2. Mentally disordered patients<br>3. Patients with TMJ disorders<br>4. Dysgnathic patients with Angle class II or III<br>5. Patients who have received or need orthodontical treatment<br>6. Patients who have been already sufficiently treated<br>7. Patients who do not accept a removable deture<br>8. Patients who demand the replacement of all molars<br>9. Patients with general health American Society of Anesthesiologists (ASA) classification group four
Exclusion criteria: 1. Incomplete staging<br>2. Major organ dysfunction (Chronic Obstructive Pulmonary Disease [COPD] with respiratory insufficiency, symptomatic Coronary Heart Disease [CHD], cardiomyopathy or heart failure [ejection fraction less than 50%], severe hypertension, non-treatable infections, white blood count less than 3000/mm^3 or platelets less than 100,000/mm^3, creatinine clearance less than 60 ml/min, bilirubin more than 2 mg/dl, Glutamic-Oxaloacetic Transaminase [GOT]/aspartate aminotransferase [AST] more than 100 U/l, Glutamic-Pyruvic Transaminase [GPT]/alanine aminotransferase [ALT] more than 100 U/l, Human Immunodeficiency Virus [HIV]-infection)<br>3. Composite lymphoma<br>4. Prior chemotherapy or radiotherapy<br>5. Any history of another malignancy in the last five years (except for cervical carcinoma in situ and fully resected melanoma TNMpT1)<br>6. Pregnancy or breastfeeding<br>7. World Health Organization (WHO) performance status more than two<br>8. Long term use of corticosteroids (e.g. for arthritis) or antineoplastic substances (e.g. methotrexate)<br>9. Expected non compliance<br>10. Current therapy for epilepsy<br>11. Intolerabilities against study drugs<br>12. Inability to give truly informed consent
Exclusion criteria: <br>1. More than 1 previous chemotherapeutic treatment for metastatic<br>or relapsed disease. <br><br>2. Major surgery < 4 weeks prior to enrollment<br><br>3. Immunotherapy <2 weeks prior to enrollment<br><br>4. Severe pulmonary obstructive or restrictive disease<br><br>5. Uncontrolled inflammatory disease (autoimmune or infectious)<br><br>6. Clinically significant cardiac disease (NYHA stadium > 2)<br><br>7. Laboratory tests (hematology, chemistry) outside specified limits:<br>WBC < or equal 3 x 10 EXP 9/L <br>ANC < or equal 1.5 x 10 EXP 9/L<br>Platelets < or equal  100 x 10 EXP 9/L<br>Hb < or equal  9.0 g/dl (< or equal  5.6 mmol/l)<br>PTT/INR > 1.5 x ULN <br>                AST or ALT > 2.5 x ULN<br>                Alkaline Phosphatase > 2 x ULN<br>                Total Bilirubin > 1.5 x ULN <br><br>8. Pregnancy or nursing status<br><br>9. Known positive HIV testing<br><br>10.  Known hypersensitivity to any component of the EndoTAG-1 or taxane formulations<br><br>11.  History of malignancy other than breast cancer < 5 years prior to enrollment, except skin cancer (i.e. basal or squamous cell carcinoma) treated locally <br><br>12.  Known progressive cerebral metastasis (patients with cerebral metastases in a stable state or after successful surgical or radiological treatment are allowed to participate in the study) <br><br>13.  History of active or significant neurological disorder and/or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of central nervous system during the trial<br><br>14.  Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry<br><br>
Exclusion criteria: <br>                1. Family history of bipolar affective disorder or schizophrenia in first-degree relatives<br>                2. A personal history of hypomanic or manic episode<br>                3. Schizophrenia<br>                4. Mood incongruent psychotic symptoms<br>                5. Primary substance misuse<br>                6. Primary organic brain disease<br>                7. Current treatment with an antipsychotic or a mood stabiliser<br>                8. Pregnancy or lactation<br>                9. Medical contraindications or a history of lack of efficacy or adverse reaction to both study medications<br>                10. Previous adverse reactions or non-response to either escitalopram or citalopram are considered as contraindications to escitalopram<br>
Exclusion criteria: 1. Maintenance treatment is considered unnecessary<br>2. A particular maintenance treatment is definitely indicated or contraindicated, or the<br>patient is unwilling to take one or other of the study treatments<br>3. A medical disorder or condition coexists which contraindicates either of the investigational drugs, e.g., pregnancy<br>4. The patient is not normally resident in the UK or is of no fixed abode
Exclusion criteria: <br>                •Pre-treatment differing from study protocol<br><br>                •Known hypersensitivity or contraindication to study drugs and/or dacarbazine<br><br>                •Prior chemotherapy or radiotherapy which prevents adequate performance of radiotherapy as outlined by the present protocol. This may mainly apply to patients with secondary malignant glioma after a previous malignant brain tumour, e.g. medulloblastoma, supratentorial PNET. If previous treatment does not prevent the adequate performance of the outlined treatment protocol patients with secondary malignant glioma will be eligible for the present trial.<br><br>                •Other (simultaneous) malignancies<br><br>                •Pregnancy and / or lactation<br><br>                •Patients who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile)<br><br>                •Current or recent (within 30 days prior to start of trial treatment) treatment with another investigational drug or participation in another investigational trial<br><br>                •Very poor clinical condition as defined by demand of mechanical ventilation and/or demand for intravenous catecholamines and/or very severe neurological damage equivalent to a coma and/or tetraplegia with complete incapability for communication (deafness, blindness, mutism)<br><br>                •Severe concomitant diseases (e.g. immune deficiency syndrome)<br><br>                •Known HIV positivity<br><br>                •Country-specifically very young patients may be excluded to comply with national laws or formal insurance requirements<br><br><br>
Exclusion criteria: 1. Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection<br>2. Miscellaneous acute or chronic infections<br>3. Known coagulation disturbances<br>4. Known incompliance with respect to fluid restriction
Exclusion criteria: 1. Aged less than 60 years<br>2. No written consent from patient<br>3. Inability to communicate safely in German<br>4. Unwillingness to allow storage and sharing of anonymised disease data in the context of the clinical study<br>5. Simultaneous participation of the patient in another study or having been in a study which was terminated less than one month ago and not planned within the next three months<br>6. Accommodation in an institution due to an official or judicial order<br>7. Members of staff of the Charité<br>8. Advanced disease of the oesophagus of nasopharyngeal cavity<br>9. Operations in the area of the oesophagus or nasopharynx within the last two months<br>10. Liver disease (Child B or C cirrhosis, End-Stage Liver Disease [MELD] score greater than 10)<br>11. Condition after acute or chronic pancreatitis<br>12. History of bleeding tendency<br>13. Von Willebrands disease<br>14. Neurological or psychiatric disease<br>15. Chronic heart failure New York Heart Association (NYHA) class IV<br>16. American Society of Anaesthesiologists (ASA) classification greater than III<br>17. Renal failure (serum creatinine greater than 2.0 mg/dl or greater than 150 µmol/l or dependency of haemodialysis)<br>18. Existence of a pulmonary oedema in the preoperative chest x-ray<br>19. Allergy to hydroxyethyl starch or other ingredients of the intravenous solutions<br>20. History of intracranial haemorrhage within one year
Exclusion criteria: <br>                To investigate antibiotic prescribing the DREAM trial includes the entire patient population of participating dental practices.<br><br>                Exclusion criteria for patients in the subgroup include:<br>                1. Younger than 18 years<br>                2. Not being able to give informed consent (e.g. in case of dementia)<br>                3. Consulting the dentist during the emergency service<br>                4. Suffering from immunosuppression or malignoma<br>                5. Having a disease-related life expectancy of less than 12 months<br>
Exclusion criteria: 1. Inability to give informed consent and absence of a caregiver holding power of attorney<br>2. Any of the following conditions as defined by ICD-10 criteria<br>2.1. Presence of substance abuse (F 10)<br>2.2. Schizophrenia and associated conditions (F20)<br>2.3. Bipolar disorder (F30,31)
Exclusion criteria: 1. Patients with secondary diabetes mellitus<br>2. Any previous insulin treatment before the first injection of study drug<br>3. History of intolerance or contraindications to oral hypoglycaemic medications<br>4. Clinical evidence of any severe diabetes-related complication<br>5. Allergy to investigational drug<br>6. History of severe allergy or asthma<br>7. Known immune deficiency from any disease, or a condition associated with an immune deficiency<br>8. Use of immunosuppressive or immunomodulating agents or cytotoxic therapy, or any medication which, in the opinion of the investigator, might interfere with the study
Exclusion criteria: - contralateral breast cancer or presence of metastatic disease (exception: contralateral in situ ductal cancer)<br>- surgical axillary staging prior to study entry (exception: FNA of 1 axillary node is permitted, and, but not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes)<br>- pregnant and lactating women.<br>- women with childbearing potential unless appropriate contraception as described in protocol<br>- treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy for current diagnosed breast cancer.<br>- previous investigational product within 4 weeks of randomisation<br>- patients on therapy with a strong CYP3A4 ihibitor, and on therapy with warferin<br>- previous or concomitant malignancy of other type that could affect compliance.<br>- pre-existing motor or sensory neuropathy of Grade >1 for any reason<br>- patients with hypersensitivity due to drugs containing polyoxyethylene castor oil, or hardened castor oil.<br>- other serious illness or medical condition (examples included in the protocol)<br>- patients with a history of uncontrolled seizures, contral nervous system disorders or psychaitric disability judged to be clinically significant<br>- serious uncontrolled infections or poorly controlled diabetes mellitus<br>- Abonrmal laboratory values at baseline: ANC <1.5 x 109/L; platelet count < 100 x 109/L; Hb < 10g/dL; serum total bilirubin > 1.5xULN (except documented Gilbert's syndrome); ALT > 1.25 x ULN; serum creatinine > 1.5x ULN<br>- Baseline LVEF < 50% by echocardiography or MUGA scan<br><br> <br>-
Exclusion criteria: ? Squamous cell NSCLC. <br/ ><br>? Prior therapy with monoclonal antibodies, signal transduction inhibitors, or any <br/ ><br>therapies targeting the EGFR, VEGF, or VEGFR <br/ ><br>? Previous chemotherapy for advanced NSCLC (patients who have received adjuvant chemotherapy &#8805; 1 year prior to randomization are eligible) <br/ ><br>? Major surgery or any investigational therapy in the 4 weeks prior to randomization <br/ ><br>? Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed) <br/ ><br>? Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants <br/ ><br>
Exclusion criteria: 1. Diseases that require immunosuppressive therapy (systemic administration of steroids or cyclosporine A)<br>2. Transfer to an intensive care unit after birth<br>3. Known immune disturbances or defects (Lymphopenia, Thrombopenia)<br>4. Concomitant medication or treatment (except for prophylaxis)<br>5. Inadequate ability or willingness of the parents to communicate or to cooperate<br>6. Family anamnesis of a congenital deficiency in immune defence
Exclusion criteria: <br>•Recent cardiac surgery in = 6 weeks<br>•Major adverse cardiac events (MACE) = 6 weeks (e.g. ICD shock, myocardial infarction, stroke, revascularization)<br>•Cardiovascular procedure or hospitalization planned in the future<br>•Coronary artery disease (CAD) with need for revascularization<br>•Heart failure secondary to significant uncorrected primary valvular disease<br>•Co-morbidities associated with reduced life expectancy <1 year<br>•Inability to participate in exercise training (e.g. COPD GOLD III-IV, claudication =2b, other functional or mental limitations, significant cardiac ischemia, arrhythmias)<br>•Presence of persistent atrial fibrillation<br>•EMB examination showing active (mRNA positive) adeno or enterovirus (Coxsackievirus B3)<br>•Positive pregnancy test in female study participants<br>•Patients who take any of the prohibited concomitant medications: Immunosuppressant agents (e.g.: Corticosteroids, Cyclosporine), Interferon, anti-viral agents (e.g.: Valganciclovir, Lamivudine), and long-acting nitrates (e.g.: Isosorbide di/trinitrate).<br>•Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel.<br>•Subjects unable to freely give their informed consent (e.g. individuals under legal guardianship).<br>•Patients who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.<br>•Patients who are dependent on sponsor, investigator or study site<br><br>
Exclusion criteria: 1. Contraindications for CPET according to current guidelines<br>2. Congestive heart failure<br>3. Coronary heart disease<br>4. Myocardial infarction within the last 6 months<br>5. Pulomonary diseases other than CTD<br>6. Primary myopathy